Skip to main content
. Author manuscript; available in PMC: 2009 Jun 8.
Published in final edited form as: Eur J Neurosci. 2009 Mar;29(6):1119–1130. doi: 10.1111/j.1460-9568.2009.06664.x

FIG. 5.

FIG. 5

Human recombinant 3K3A-APC exerts antiapoptotic activity in hypoxic human BECs. (a) Terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick-end labeling (TUNEL) and Hoechst staining of BECs subjected to OGD for 8:00 h in the absence or presence of human 3K3A-APC (10 nm). (b) Dose-dependent cytoprotective effects of human 3K3A-APC and wt-APC on OGD BECs were quantified with an LDH release assay after 8:00 h of exposure to OGD (*P < 0.01 by two-way ANOVA). The basal rate of BEC death under normoxic conditions is also shown. (c) IC50 values of 3K3A-APC and wt-APC were calculated from Fig. 1b. All values are mean ± SEM.